Jul 01, 2020 14:02 JST

Source: Eisai

Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID

GCAR, Eisai and UPMC, on Behalf of Remap-Cap Investigator Network, Announce Eritoran's Inclusion in Remap-Covid, an Adaptive Clinical Trial to Test Interventions for Patients With Moderate and Severe COVID Infection

Eisai's Eritoran Selected as the First Investigational Immune Modulation Therapy to Be Evaluated Across Multiple International Trial Sites

TOKYO, Jul 01, 2020 - (JCN Newswire) - The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19.

Eritoran, an investigational TLR4 antagonist discovered and developed by Eisai, has been selected as the first investigational immune modulation therapy to be evaluated in the moderate patient group of REMAP-COVID. The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow. Previously observed to be safe in a large Phase 3 randomized trial in sepsis, eritoran is designed to suppress the over-production and release of various pro-inflammatory mediators (cytokine storm) with the aim to protect against damage in COVID-19 patients' lungs and other organs.

"We are excited to initiate our partnership with Eisai and to test this promising intervention in the trial," stated Christopher Seymour, M.D, MSC, Associate Professor, Department of Critical Care Medicine(New Window) at the University of Pittsburgh and UPMC, and U.S. principal investigator of the REMAP-CAP:COVID study. "By utilizing an adaptive design rather than using a traditional trial approach, we are more likely to get to answers faster, while keeping our patients as safe as possible. REMAP-COVID is an optimal study to identify potential treatments for COVID-19 as safely, quickly, and effectively as possible."

"Eisai is proud to be part of this collaborative initiative to fight the unprecedented COVID-19 pandemic. We are pleased that our investigational immune modulation therapeutic TLR4 antagonist, eritoran, will be studied alone and in combination with other drugs to evaluate the effectiveness in COVID-19 hospitalized patients," said Lynn Kramer, M.D, Chief Clinical Officer, Neurology Business Group, Eisai. "As part of our human health care mission, we are committed to making a difference for patients, their families, and health care professionals across the globe."

REMAP-CAP was designed to find optimal treatments for severe pneumonia both in non-pandemic and pandemic settings. When COVID-19 began, REMAP-CAP rapidly pivoted to its pandemic mode (the REMAP-COVID substudy), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. This trial is a multicenter, randomized, standard of care vs. multi-active comparators platform study. The primary endpoint for the REMAP-COVID substudy is organ failure free days over a 21 day observational period. Eritoran will be evaluated in hospitalized patients in the immune modulation domain of REMAP-COVID.

REMAP-CAP is led by the world's leading critical care trialists and experts in pandemic and infectious disease outbreaks, virology, immunology, emergency medicine, and Bayesian statistics. REMAP-CAP has enrolled over 1100 patients at 218 sites across North America, Europe, Australia and New Zealand. This vital research is being conducted in collaboration with Berry Consultants, leaders in statistical design for adaptive platform trials, and is being supported by governments and non-profits worldwide. Most recently, the Breast Cancer Research Foundation, committed $1M to help launch U.S. trial sites through the long-established, innovative trial infrastructure of the Translational Breast Cancer Research Consortium.

"The REMAP study strategy for COVID-19 provides a platform on which to build existing relevant knowledge, plus swiftly and simultaneously evaluate the safety and effectiveness of multiple investigational treatments against the virus, thus enabling us to learn as much as possible in COVID-19 clinical trials," explained Mark McClellan, M.D, PhD, Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University.

"GCAR is honored to participate in this global effort and to serve as trial sponsor of REMAP-CAP:COVID in the U.S. alongside the University of Pittsburgh serving as the U.S. Regional Coordinating Center," shared Meredith Buxton, PhD, MPH, CEO of GCAR. "We are pleased to leverage our extensive experience in running platform trials to support this important endeavor. By working with key partners in academia, industry and philanthropy we will strive to identify improved treatment options for patients with COVID-19."

To learn more about REMAP-CAP and the REMAP-COVID substudy, please visit www.remapcap.org and follow @remap_cap.

About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Rachel Rosenstein-Sisson
[email protected]
+1 818-398-134

Eisai Co.,Ltd.
TEL: +81(0) 3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
November 30 2020 13:04 JST
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
November 30 2020 10:16 JST
AbbVie and Eisai Announce an approval for additional indication of HUMIRA
November 27 2020 21:05 JST
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
November 18 2020 19:11 JST
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
November 18 2020 19:00 JST
Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients
November 16 2020 09:06 JST
LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
November 11 2020 08:56 JST
Eisai: Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
November 09 2020 08:08 JST
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference
October 28 2020 09:07 JST
Eisai and JD Health Establish JV Company in China to Implement Health Service Platform
October 28 2020 08:01 JST
More Press release >>

Latest Press Release

More Latest Release >>